Healthcare & Life Sciences
Executing a mergers and acquisitions, M&A strategy without disrupting business operations requires the counsel of advisors with specialized technical expertise, extensive contacts, industry knowledge and a proven track record of successfully negotiating and closing deals.
Our Life Sciences and Healthcare division provides strategic guidance through the merger and acquisition process across a broad spectrum of health services industries:
- Medical Devices & Equipment
- Healthcare Technology
- Biotech & Pharmaceuticals
- Life Science Tools & Diagnostics
- Contract Research Services
- Buy Side Engagements
- Sell Side Engagements
- Partnering Transactions
- Strategic Advisory Plans
- Capital Fund-Raising
- Business and Technology Valuations
David H. Crean, Ph.D.
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life science R&D and corporate development transactional experience in the pharmaceutical industry where he is responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. Dr. Crean’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.
Jack J. Florio
Jack J. Florio is a Managing Director at Objective Capital Partners in the firm’s healthcare & life science investment banking group. Mr. Florio has 40+ years of global life sciences experience in major pharmaceutical, biotechnology, medical devices and digital health companies. He has held senior management roles in both small and large companies including CEO, Corporate Development and Business Development. Mr. Florio holds FINRA Series 7 and 63 licenses.